Elsevier

Steroids

Volume 77, Issue 4, 10 March 2012, Pages 306-311
Steroids

Review
Medical management of metabolic dysfunction in PCOS

https://doi.org/10.1016/j.steroids.2011.11.014Get rights and content

Abstract

Polycystic ovary syndrome (PCOS) is associated with metabolic derangements including insulin resistance, dyslipidemia, systemic inflammation and endothelial dysfunction. There is a growing need to develop pharmacologic interventions to improve metabolic function in women with PCOS. Medications that have been tested in patients with PCOS include metformin, thiazolidinediones, acarbose, naltrexone, orlistat, vitamin D and statins.

Metformin decreases hepatic gluconeogenesis and free fatty acid oxidation while increasing peripheral glucose uptake. Early studies in PCOS suggested that metformin indirectly reduces insulin level, dyslipidemia and systemic inflammation; however, recent placebo-controlled trials failed to demonstrate significant metabolic benefit. Thiazolidinediones act primarily by increasing peripheral glucose uptake. Most studies in PCOS have demonstrated that thiazolidinediones reduce insulin resistance; however, effects on dyslipidemia were disappointing. Use of thiazolidinediones is associated with weight gain and major complications. Acarbose reduces digestion of polysaccharides. Studies in PCOS yielded inconsistent effects of acarbose on insulin sensitivity and no significant improvement of dyslipidemia. Naltrexone reduces appetite and modulates insulin release; its use in PCOS may reduce hyperinsulinemia. Orlistat decreases absorption of dietary fats; studies in PCOS suggest beneficial effects on insulin sensitivity. Vitamin D may improve insulin sensitivity but mixed results on lipid profile in PCOS have been reported. Statins are competitive inhibitors of the key enzyme regulating the mevalonate pathway; their effects are related to reduced cholesterol production as well as anti-inflammatory and anti-oxidant properties. In women with PCOS, statins reduce hyperandrogenism, improve lipid profile and reduce systemic inflammation while the effects on insulin sensitivity are variable. Use of statins is contraindicated in pregnancy.

Highlights

► Metformin may improve metabolic profile in women with hyperinsulinemia. ► Thiazolidinediones improve insulin sensitivity but carry significant risks. ► Statins improve several metabolic abnormalities but likely not insulin resistance. ► Benefits of use of orlistat, acarbose, naltrexone and orlistat are not proven. ► Long-term benefits of use of any medical treatment in PCOS is not certain.

Introduction

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting between 6% and 8% of women in reproductive age [1]. It is associated not only with reproductive and cosmetic sequelae, but also with significantly increased risk of metabolic dysfunction including insulin resistance with consequent compensatory hyperinsulinemia, dyslipidemia, systemic inflammation, increased oxidative stress, and endothelial dysfunction (Fig. 1) [2], [3]. In the long-term, women with PCOS may develop type 2 diabetes mellitus, hypertension and atherosclerosis; ultimately, they are more likely to suffer from cardiovascular and cerebrovascular diseases [4], [5], [6].

First-line therapy for metabolic dysfunction typically consists of lifestyle modifications including a diet and exercise regimen. Unfortunately, long-term success of lifestyle modifications is often not achieved. Consequently, there is an urgent need to develop and validate appropriate pharmacologic interventions to improve metabolic function in women with PCOS. This brief review will present several currently available medical treatments of selected features of metabolic dysfunction and will discuss pros and cons of their use in PCOS.

Section snippets

Metformin

Metformin is a biguanide widely used in treatment of type 2 diabetes mellitus and, more recently, in treatment of other conditions including PCOS. The primary mechanism of action of metformin is believed to be related to reduction of hepatic gluconeogenesis [7], [8]. In addition, metformin improves glucose uptake by peripheral tissues, decreases fatty acid synthesis and increases fatty acid oxidation. Metformin may also improve insulin sensitivity of skeletal muscles and reduce appetite.

Thiazolidinediones

Thiazolidinediones encompass a family of related compounds acting as peroxisome-proliferator-activated receptor-γ (PPRAγ) agonists. Thiazolidinediones improve insulin sensitivity at the level of peripheral tissues including skeletal muscle and adipocytes. Beneficial effects of thiazolidinediones including rosiglitazone and pioglitazone on insulin sensitivity in women with PCOS have been documented in multiple studies including placebo-controlled trials [21], [23], [24], [25], [26].

Acarbose

Acarbose is a complex oligosaccharide inhibiting α-glucosidase in the brush border of the small intestine. It decreases digestion of polysaccharides and hence reduces glucose absorption in the gut and decreases postprandial insulin levels. To date few studies addressed the effects of acarbose on women with PCOS [32], [33], [34], [35], [36]. In only two studies acarbose reduced insulin level and/or parameters of insulin resistance [32], [35] while in other studies no improvement was noted [33],

Naltrexone

Naltrexone is a competitive nonselective antagonist of opioid receptors. Use of naltrexone in treatment of PCOS is based on the evidence that PCOS is characterized by increased activity of sympathetic nervous system, altered central opioid tone and elevated beta-endorphin release [37], [38], [39] There is also a growing body of evidence demonstrating that beta-endorphins exert profound effects on insulin release [37].

In several studies oral administration of naltrexone in women with PCOS

Orlistat

Orlistat is a gastric and pancreatic lipase inhibitor reducing absorption of dietary fats by inhibition of hydrolysis of triglycerides. It has been approved for management of obesity and has been recently tested in several trials evaluating women with PCOS [46], [47], [48], [49]. In three of these studies, orlistat improved parameters of insulin sensitivity and reduced insulin level with concomitant decrease of BMI [46], [47], [49]. However, in one of the studies, orlistat while reducing BMI,

Vitamin D

The primary role of vitamin D pertains to regulation of calcium homeostasis and bone metabolism. Vitamin D promotes intestinal absorption of dietary calcium. Vitamin D receptors are present in most tissues in the body and effects of vitamin D include inhibition of cell proliferation, induction of cell differentiation and immunomodulation. Low levels of vitamin D are associated with insulin resistance while administration of Vitamin D may improve insulin sensitivity; however, the mechanisms of

Statins

Statins are competitive inhibitors of the rate-limiting enzyme in the cholesterol biosynthetic pathway: 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Statins improve the lipid profile, primarily by decreasing total cholesterol and LDL-cholesterol levels [57], [58]. Statins also exert many other potentially beneficial effects including improvement of nitric oxide-mediated endothelial function as well as anti-inflammatory and anti-proliferative actions [59], [60]. In the long-term,

Conclusions

At first glance, review of the literature may suggest the availability of a plethora of medical treatments to correct metabolic dysfunction associated with PCOS. However, upon closer inspection of the studies, the evidence for real long-term benefit of currently available treatments is, at best, very limited. Metformin appears to alleviate some aspects of metabolic dysfunction, but the improvement is modest while the side effects are very common and significant. Furthermore, response to

Acknowledgment

Supported by Eunice Kennedy Shriver National Institute of Child Health and Human Development grant R01-HD050656.

References (65)

  • D. Panidis et al.

    Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

    Fertil Steril.

    (2008)
  • K. Kotsa et al.

    Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome

    Fertil Steril

    (2009)
  • M.A. Albert et al.

    The pravastatin inflammation CRP evaluation (PRINCE): rationale and design

    Am Heart J

    (2001)
  • C. Kaya et al.

    Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study

    Fertil Steril

    (2009)
  • R. Azziz et al.

    The prevalence and features of the polycystic ovary syndrome in an unselected population

    J Clin Endocrinol Metab

    (2004)
  • H.F. Escobar-Morreale et al.

    Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis

    Fertil Steril

    (2011)
  • R.C. Christian et al.

    Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome

    J Clin Endocrinol Metab

    (2003)
  • R.A. Wild et al.

    Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society

    J Clin Endocrinol Metab

    (2010)
  • P.C. de Groot et al.

    PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis

    Hum Reprod Update

    (2011)
  • S. Palomba et al.

    Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review

    Endocr Rev

    (2009)
  • E. Diamanti-Kandarakis et al.

    Metformin in polycystic ovary syndrome

    Ann N Y Acad Sci

    (2010)
  • Anonymous

    Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group

    N Engl J Med

    (2002)
  • L.C. Morin-Papunen et al.

    Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study

    J Clin Endocrinol Metab

    (2000)
  • P. Moghetti et al.

    Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation

    J Clin Endocrinol Metab

    (2000)
  • F. Orio et al.

    Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study

    J Clin Endocrinol Metab

    (2005)
  • M. Luque-Ramirez et al.

    Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome

    J Clin Endocrinol Metab

    (2007)
  • E. Diamanti-Kandarakis et al.

    Metformin administration improves endothelial function in women with polycystic ovary syndrome

    Eur J Endocrinol

    (2005)
  • B. Banaszewska et al.

    Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment

    J Clin Endocrinol Metab.

    (2011)
  • T. Tang et al.

    Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study

    Hum Reprod

    (2006)
  • J. Lord et al.

    The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome–a randomised, double-blind, placebo-controlled trial

    BJOG

    (2006)
  • K. Hoeger et al.

    The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials

    J Clin Endocrinol Metab

    (2008)
  • Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone,...
  • Cited by (46)

    • Polycystic ovary syndrome and nonalcoholic fatty liver disease

      2023, Polycystic Ovary Syndrome: Basic Science to Clinical Advances across the Lifespan
    • Blockade of mineralocorticoid receptor by low-dose spironolactone rescues hypothalamic-ovarian dysfunction in PCOS experimental rat model

      2022, Endocrine and Metabolic Science
      Citation Excerpt :

      Several reviews regarding treatment strategies advocate for the use of statin drugs in PCOS. Statins show promising improvements in serum levels of androgens and LH/FSH ratios (Duleba, 2012). The use of these therapeutic agents has been associated with several adverse effects: including abdominal pain, metallic taste in the mouth, diarrhoea and vomiting (Hoeger et al., 2021; Pathak, 2021).

    • Biosynthesized silver nanoparticles (using Cinnamomum zeylanicum bark extract) improve the fertility status of rats with polycystic ovarian syndrome

      2021, Biocatalysis and Agricultural Biotechnology
      Citation Excerpt :

      Polycystic ovarian syndrome (PCOS) is one of the most prevalent hormonal imbalance diseases affecting 5–20% of women at reproductive age in the world. It is characterized by polycystic ovarian morphology, hyperandrogenism, hirsutism, menstrual irregularity, ovarian dysfunction and infertility (Azziz et al., 2016; Duleba, 2012; Rostamtabar et al., 2021). About 50%–70% of anovulatory infertility cases were reported to be linked to PCOS (Teede et al., 2008), especially those accompanied by a low ovulation induction rate, low pregnancy rate, and high abortion rate.

    • Drug-repositioning opportunities for cancer therapy: Novel molecular targets for known compounds

      2016, Drug Discovery Today
      Citation Excerpt :

      Thanks to its overall safety at therapeutic doses, with rare severe adverse effects (lactic acidosis), metformin was approved as antidiabetic drug during the 1970s in Europe, and in 1995 in the USA. Moreover, metformin does not to induce hypoglycemia in either diabetics or nondiabetics and, is now also approved for the treatment of polycystic ovarian syndrome, metabolic syndrome, and T2DM prevention [80–82]. Metformin efficiently reduces blood glucose and increases insulin sensitivity in patients with T2DM, mainly through the inhibition of hepatic gluconeogenesis and the stimulation of glucose uptake in peripheral tissues, increasing the affinity of insulin toward its receptor.

    View all citing articles on Scopus
    View full text